Bürgi Milagros, Zapol'skii Viktor A, Hinkelmann Bettina, Köster Mario, Kaufmann Dieter E, Sasse Florenz, Hauser Hansjörg, Etcheverrigaray Marina, Kratje Ricardo, Bollati-Fogolín Mariela, Oggero Marcos
Cell Culture Laboratory, School of Biochemistry and Biological Sciences, Universidad Nacional del Litoral, Ciudad Universitaria - C.C. 242 - (S3000ZAA) Santa Fe, Provincia de Santa Fe, Argentina.
Technical University of Clausthal, Leibnizstraße 6, D-38678 Clausthal-Zellerfeld, Germany.
J Biotechnol. 2016 Sep 10;233:6-16. doi: 10.1016/j.jbiotec.2016.06.021. Epub 2016 Jun 23.
Type I Interferons (IFNs-I) are species-specific glycoproteins which play an important role as primary defence against viral infections and that can also modulate the adaptive immune system. In some autoimmune diseases, interferons (IFNs) are over-produced. IFNs are widely used as biopharmaceuticals for a variety of cancer indications, chronic viral diseases, and for their immuno-modulatory action in patients with multiple sclerosis; therefore, increasing their therapeutic efficiency and decreasing their side effects is of high clinical value. In this sense, it is interesting to find molecules that can modulate the activity of IFNs. In order to achieve that, it was necessary to establish a simple, fast and robust assay to analyze numerous compounds simultaneously. We developed four reporter gene assays (RGAs) to identify IFN activity modulator compounds by using WISH-Mx2/EGFP, HeLa-Mx2/EGFP, A549-Mx2/EGFP, and HEp2-Mx2/EGFP reporter cell lines (RCLs). All of them present a Z' factor higher than 0.7. By using these RGAs, natural and synthetic compounds were analyzed simultaneously. A total of 442 compounds were studied by the Low Throughput Screening (LTS) assay using the four RCLs to discriminate between their inhibitory or enhancing effects on IFN activity. Some of them were characterized and 15 leads were identified. Finally, one promising candidate with enhancing effect on IFN-α/-β activity and five compounds with inhibitory effect were described.
I型干扰素(IFNs-I)是种属特异性糖蛋白,作为抵御病毒感染的主要防线发挥重要作用,并且还可以调节适应性免疫系统。在某些自身免疫性疾病中,干扰素(IFNs)会过度产生。IFNs作为生物药物被广泛用于多种癌症适应症、慢性病毒性疾病,以及在多发性硬化症患者中发挥免疫调节作用;因此,提高其治疗效率并降低其副作用具有很高的临床价值。从这个意义上讲,寻找能够调节IFNs活性的分子很有意思。为了实现这一目标,有必要建立一种简单、快速且可靠的检测方法,以便同时分析众多化合物。我们开发了四种报告基因检测法(RGAs),通过使用WISH-Mx2/EGFP、HeLa-Mx2/EGFP、A549-Mx2/EGFP和HEp2-Mx2/EGFP报告细胞系(RCLs)来鉴定IFN活性调节剂化合物。所有这些检测法的Z'因子均高于0.7。通过使用这些RGAs,同时分析了天然和合成化合物。使用这四种RCLs通过低通量筛选(LTS)检测法共研究了442种化合物,以区分它们对IFN活性的抑制或增强作用。其中一些化合物得到了表征,并鉴定出15个先导化合物。最后,描述了一种对IFN-α/-β活性有增强作用的有前景的候选化合物和五种具有抑制作用的化合物。